Hamid Khodakarami1, Navid Shokouhi1, Malcolm Horne2,3,4. 1. Global Kinetics Pty Ltd, 31 Queen St., Melbourne, Victoria, Australia. 2. Florey Institute of Neuroscience and Mental Health, Victoria, Australia. malcolm.horne@florey.edu.au. 3. The Department of Medicine, The University of Melbourne, St Vincent's Hospital, Fitzroy, VIC, 3010, Australia. malcolm.horne@florey.edu.au. 4. Department of Neurology, St Vincent's Hospital, Fitzroy, VIC, Australia. malcolm.horne@florey.edu.au.
Abstract
BACKGROUND: Fluctuations in motor function in Parkinson's Disease (PD) are frequent and cause significant disability. Frequently device assisted therapies are required to treat them. Currently, fluctuations are self-reported through diaries and history yet frequently people with PD do not accurately identify and report fluctuations. As the management of fluctuations and the outcomes of many clinical trials depend on accurately measuring fluctuations a means of objectively measuring time spent with bradykinesia or dyskinesia would be important. The aim of this study was to present a system that uses wearable sensors to measure the percentage of time that bradykinesia or dyskinesia scores are above a target as a means for assessing levels of treatment and fluctuations in PD. METHODS: Data in a database of 228 people with Parkinson's Disease and 157 control subjects, who had worn the Parkinson's Kinetigraph ((PKG, Global Kinetics Corporation™, Australia) and scores from the Unified Parkinson's Disease Rating Scale (UPDRS) and other clinic scales were used. The PKG's provided score for bradykinesia and dyskinesia every two minutes and these were compared to a previously established target range representing a UPDRS III score of 35. The proportion of these scores above target over the 6 days that the PKG was worn were used to derive the percent time in bradykinesia (PTB) and percent time in dyskinesia (PTD). As well, a previously describe algorithm for estimating the amplitude of the levodopa response was used to determine whether a subject was a fluctuator or non-fluctuator. RESULTS: Using this approach, a normal range of PTB and PTD based on Control subject was developed. The level of PTB and PTD experienced by people with PD was compared with their levels of fluctuation. There was a correlation (Pearson's ρ = 0.4) between UPDRS II scores and PTB: the correlation between Parkinson Disease Questionnaire scores and UPDRS Total scores and PTB and slightly lower. PTB and PTD fell in response to treatment for bradykinesia or dyskinesia (respectively) with greater sensitivity than clinical scales. CONCLUSIONS: This approach provides an objective assessment of the severity of fluctuations in Parkinson's Disease that could be used in in clinical trials and routine care.
BACKGROUND: Fluctuations in motor function in Parkinson's Disease (PD) are frequent and cause significant disability. Frequently device assisted therapies are required to treat them. Currently, fluctuations are self-reported through diaries and history yet frequently people with PD do not accurately identify and report fluctuations. As the management of fluctuations and the outcomes of many clinical trials depend on accurately measuring fluctuations a means of objectively measuring time spent with bradykinesia or dyskinesia would be important. The aim of this study was to present a system that uses wearable sensors to measure the percentage of time that bradykinesia or dyskinesia scores are above a target as a means for assessing levels of treatment and fluctuations in PD. METHODS: Data in a database of 228 people with Parkinson's Disease and 157 control subjects, who had worn the Parkinson's Kinetigraph ((PKG, Global Kinetics Corporation™, Australia) and scores from the Unified Parkinson's Disease Rating Scale (UPDRS) and other clinic scales were used. The PKG's provided score for bradykinesia and dyskinesia every two minutes and these were compared to a previously established target range representing a UPDRS III score of 35. The proportion of these scores above target over the 6 days that the PKG was worn were used to derive the percent time in bradykinesia (PTB) and percent time in dyskinesia (PTD). As well, a previously describe algorithm for estimating the amplitude of the levodopa response was used to determine whether a subject was a fluctuator or non-fluctuator. RESULTS: Using this approach, a normal range of PTB and PTD based on Control subject was developed. The level of PTB and PTD experienced by people with PD was compared with their levels of fluctuation. There was a correlation (Pearson's ρ = 0.4) between UPDRS II scores and PTB: the correlation between Parkinson Disease Questionnaire scores and UPDRS Total scores and PTB and slightly lower. PTB and PTD fell in response to treatment for bradykinesia or dyskinesia (respectively) with greater sensitivity than clinical scales. CONCLUSIONS: This approach provides an objective assessment of the severity of fluctuations in Parkinson's Disease that could be used in in clinical trials and routine care.
Authors: Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek Journal: N Engl J Med Date: 2004-12-09 Impact factor: 91.245
Authors: L Raciti; A Nicoletti; G Mostile; R Bonomo; D Contrafatto; V Dibilio; A Luca; G Sciacca; C E Cicero; R Vasta; M Zappia Journal: Parkinsonism Relat Disord Date: 2016-03-18 Impact factor: 4.891
Authors: Angelo Antonini; Pablo Martinez-Martin; Ray K Chaudhuri; Marcelo Merello; Robert Hauser; Regina Katzenschlager; Per Odin; Mark Stacy; Fabrizio Stocchi; Werner Poewe; Oliver Rascol; Cristina Sampaio; Anette Schrag; Glenn T Stebbins; Christopher G Goetz Journal: Mov Disord Date: 2011-07-20 Impact factor: 10.338
Authors: Alexander Storch; Christine B Schneider; Martin Wolz; Yannic Stürwald; Angelika Nebe; Per Odin; Andreas Mahler; Gerd Fuchs; Wolfgang H Jost; K Ray Chaudhuri; Rainer Koch; Heinz Reichmann; Georg Ebersbach Journal: Neurology Date: 2013-01-30 Impact factor: 9.910
Authors: M Kelley Erb; Daniel R Karlin; Bryan K Ho; Kevin C Thomas; Federico Parisi; Gloria P Vergara-Diaz; Jean-Francois Daneault; Paul W Wacnik; Hao Zhang; Tairmae Kangarloo; Charmaine Demanuele; Chris R Brooks; Craig N Detheridge; Nina Shaafi Kabiri; Jaspreet S Bhangu; Paolo Bonato Journal: NPJ Digit Med Date: 2020-01-17
Authors: Gökçe Kilinçalp; Anne-Christine Sjöström; Barbro Eriksson; Björn Holmberg; Radu Constantinescu; Filip Bergquist Journal: J Pers Med Date: 2022-01-02